Literature DB >> 30415483

Lung cancer after lung transplantation: An analysis of 25 years of experience in a single institution.

Eva Chatron1, Tristan Dégot1, Elena Salvaterra1, Antoine Dumazet1, Michele Porzio1, Sandrine Hirschi1, Armelle Schuller1, Gilbert Massard1, Benjamin Renaud-Picard1, Romain Kessler1.   

Abstract

BACKGROUND: The aim of our study was to describe the lung cancer characteristics in lung transplant recipients at our institution.
METHODS: Between January 1, 1992, and August 15, 2017, 463 patients underwent lung transplantation.
RESULTS: We found a total of 19 lung cancers (4.10%). Eight patients had lung cancer in the explanted lung, 8 in the native remaining lung, and 3 in the transplanted lung. Histopathological findings were: adenocarcinoma in 10, SCC in 8 patients, and 1 was undetermined. Among lung cancers in the explanted lungs, there were 6 stage I, 1 stage III, 1 stage IV. Among patients with a lung cancer in the remaining native lung, 3 had early stage disease and 5 had stage IV disease. Among lung cancers in the transplanted lung, there were: 1 stage I, 1 stage II and 1 stage IV. Overall median survival in lung transplant recipients without lung cancer was 8.77 ± 0.74 years compared to 6.19 ± 1.4 years in recipients with lung cancer.
CONCLUSION: Lung cancer following lung transplantation was uncommon. Early stage lung cancer discovered in the explanted lungs had no impact on survival. Lung cancer occurring in the transplanted or in the native remaining lung had a poor prognosis.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  immunosuppressive therapy; lung cancer; lung transplantation

Mesh:

Year:  2018        PMID: 30415483     DOI: 10.1111/ctr.13446

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  1 in total

1.  The clinicopathological study of lung cancer concealed in end-stage of interstitial lung disease.

Authors:  Bei Wang; Xiaoyan Zhang; Huang Chen; Lei Yang; Jie Li; Fei Xiao; Chaoyang Liang; Dingrong Zhong
Journal:  Transl Cancer Res       Date:  2020-02       Impact factor: 1.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.